AGN-1135

AGN-1135
Clinical data
Other names	AGN-1135; Racemic rasagiline; (±)-Rasagiline; (RS)-Rasagiline; N-Propargyl-1-aminoindane
Identifiers
	IUPAC name N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine;
CAS Number	1875-50-9;
PubChem CID	122316;
ChemSpider	13409715;
UNII	UZ2TR4YN26;
CompTox Dashboard (EPA)	DTXSID00861335 ;
Chemical and physical data
Formula	C12H13N
Molar mass	171.243 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C#CCNC1CCC2=CC=CC=C12;
	InChI InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2; Key:RUOKEQAAGRXIBM-UHFFFAOYSA-N;

AGN-1135 (also known as racemic rasagiline or as N-propargyl-1-aminoindane) is a monoamine oxidase inhibitor (MAOI) that was never marketed.^[1]^[2] It is the racemic form of rasagiline and is a mixture of the R(+)-enantiomer (rasagiline; TVP-1012) and S(–)-enantiomer (TVP-1022).^[1]^[2] Like rasagiline, AGN-1135 is a selective monoamine oxidase B (MAO-B) inhibitor.^[1] Virtually all of the MAOI activity of AGN-1135 lies in rasagiline, which is several orders of magnitude more potent as an MAO-B inhibitor than the S(–)-enantiomer.^[1] In relation to this, enantiopure rasagiline was developed and marketed for use as a pharmaceutical drug rather than AGP-1135.^[1]